Fluidity One-W Serum is a novel in-solution immunoassay platform that allows researchers to characterise and quantify antigen-antibody interactions directly in minimally diluted serum.
This new instrument provides quantitative insights into antibody affinity and concentration directly in patient serum that cannot easily be obtained with traditional antibody tests such as ELISA which combine affinity and concentration into a single, less-precise measure known as titer.
The ability to quantify both affinity and concentration allows for a better understanding of the in vivo immune response than titre alone. It helps to readily distinguish between large numbers of weak-binding antibodies and small numbers of strong-binding antibodies. In-solution measurements do not rely on attaching antigens to surfaces and thus eliminate the many drawbacks of immobilised assays including non-specific binding and binding artifacts.
Fluidity OneW Serum was developed in response to the COVID19 pandemic. It enables comprehensive profiling of the antibody response to SARSCoV2 on the basis of affinity.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
